Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| VevoctadekinNCT07098364 | Fred Hutchinson Cancer CenterPHASE1, PHASE2 | SUSPENDED Insufficient funding | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| TemozolomideNCT06639607 | Washington University School of MedicinePHASE1, PHASE2 | SUSPENDED Drugs/Equipment Unavailable | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| NivolumabNCT06639607 | Washington University School of MedicinePHASE1, PHASE2 | SUSPENDED Drugs/Equipment Unavailable | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| Tetanus boosterNCT06639607 | Washington University School of MedicinePHASE1, PHASE2 | SUSPENDED Drugs/Equipment Unavailable | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| PEP-CMV vaccineNCT06639607 | Washington University School of MedicinePHASE1, PHASE2 | SUSPENDED Drugs/Equipment Unavailable | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| MagtraceNCT06868238 | University of FloridaPHASE2 | SUSPENDED Major protocol revision involving eligibility criteria and screening procedures in progress | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| RuxolitinibNCT07025538 | City of Hope Medical CenterPHASE1 | SUSPENDED Safety Issues | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| Fludarabine PhosphateNCT04579523 | Fred Hutchinson Cancer CenterPHASE1 | WITHDRAWN Study withdrawn before opening to accrual. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| CyclophosphamideNCT04579523 | Fred Hutchinson Cancer CenterPHASE1 | WITHDRAWN Study withdrawn before opening to accrual. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10NCT04579523 | Fred Hutchinson Cancer CenterPHASE1 | WITHDRAWN Study withdrawn before opening to accrual. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| Comirnaty®NCT05534048 | Everest Medicines (Singapore) Pte. Ltd.PHASE3 | WITHDRAWN The development of this product is terminated. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| PTX-COVID19-BNCT05534048 | Everest Medicines (Singapore) Pte. Ltd.PHASE3 | WITHDRAWN The development of this product is terminated. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| OlutasidenibNCT06597734 | M.D. Anderson Cancer CenterPHASE2 | WITHDRAWN PI request | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| Verorab®NCT07124156 | European Vaccine InitiativePHASE1 | WITHDRAWN Not enough resources | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| SUM-101NCT07124156 | European Vaccine InitiativePHASE1 | WITHDRAWN Not enough resources | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| S-531011NCT07720115 | M.D. Anderson Cancer CenterPHASE2 | WITHDRAWN 0 participants | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| PembrolizumabNCT05226598 | Merck Sharp & Dohme LLCPHASE3 | TERMINATED MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support any registration, was issued; therefore, an abbreviated CSR was generated. | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| PemetrexedNCT05226598 | Merck Sharp & Dohme LLCPHASE3 | TERMINATED MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support any registration, was issued; therefore, an abbreviated CSR was generated. | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| Nab-paclitaxelNCT05226598 | Merck Sharp & Dohme LLCPHASE3 | TERMINATED MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support any registration, was issued; therefore, an abbreviated CSR was generated. | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| PaclitaxelNCT05226598 | Merck Sharp & Dohme LLCPHASE3 | TERMINATED MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support any registration, was issued; therefore, an abbreviated CSR was generated. | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| CisplatinNCT05226598 | Merck Sharp & Dohme LLCPHASE3 | TERMINATED MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support any registration, was issued; therefore, an abbreviated CSR was generated. | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| CarboplatinNCT05226598 | Merck Sharp & Dohme LLCPHASE3 | TERMINATED MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support any registration, was issued; therefore, an abbreviated CSR was generated. | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| Pembrolizumab/VibostolimabNCT05226598 | Merck Sharp & Dohme LLCPHASE3 | TERMINATED MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support any registration, was issued; therefore, an abbreviated CSR was generated. | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| FPI-2053NCT07500987 | AstraZenecaPHASE1 | TERMINATED Early termination was due to insufficient tumor uptake thought to be limited by the binding affinity of EGFR, The termination is not related to any safety or quality concerns. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| [111In]-FPI-2107NCT07500987 | AstraZenecaPHASE1 | TERMINATED Early termination was due to insufficient tumor uptake thought to be limited by the binding affinity of EGFR, The termination is not related to any safety or quality concerns. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |